Dyne Therapeutics (DYN) Cash from Financing Activities (2020 - 2026)

Dyne Therapeutics (DYN) has reported Cash from Financing Activities for 7 consecutive years, with $58.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 42.34% year-over-year to $58.1 million; the TTM figure through Jun 2026 stood at $713.5 million (up 170.6% YoY), while the FY2025 annual figure was $890.3 million, up 9.93% from the prior year.
• Cash from Financing Activities grew to $58.1 million in Q2 2026 per DYN's latest filing, from $7.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $431.0 million in Q4 2025 and bottomed at $18000.0 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $103.2 million across 5 years, with a median of $26.9 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 99.99% — and 2023, when it surged 159983.33%.
• Dyne Therapeutics' Cash from Financing Activities stood at $37.2 million in 2022, then tumbled by 99.6% to $147000.0 in 2023, then surged by 2373.47% to $3.6 million in 2024, then surged by 11752.72% to $431.0 million in 2025, then slumped by 86.52% to $58.1 million in 2026.
• Business Quant data shows DYN's Cash from Financing Activities at $58.1 million in Q2 2026, $7.1 million in Q1 2026, and $431.0 million in Q4 2025.